Revenue: As of FY2025 Q3, the actual value is USD 7.838 M, beating the estimate of USD 7.6 M.EPS: As of FY2025 Q3, the actual value is USD -0.26, missing the estimate of USD -0.245.EBIT: As of FY2025 Q3, the actual value is USD -11.33 M.<h3>Segment Revenue</h3><ul><li>Product Revenue: $5,214,000 for the three months ended September 30, 2025, compared to $5,255,000 for the same period in 2024, a decrease of 0.8%.</li><li>Service Revenue: $2,624,000 for the three months ended September 30, 2025, compared to $2,349,000 for the same period in 2024, an increase of 11.7%.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $11,505,000 for the three months ended September 30, 2025, compared to $11,323,000 for the same period in 2024, an increase of 1.6%.</li><li>Gross Margin: Positive gross margins maintained since the third quarter of 2024.</li><li>Operating Expenses: Total costs and operating expenses were $19,210,000 for the three months ended September 30, 2025, compared to $19,643,000 for the same period in 2024, a decrease of 2.2%.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $27,816,000 for the nine months ended September 30, 2025, compared to $34,244,000 for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $10,442,000 for the nine months ended September 30, 2025, compared to $31,794,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $19,328,000 for the nine months ended September 30, 2025, compared to $209,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Systems Placed: 5 systems placed in the three months ended September 30, 2025, compared to 7 systems in the same period in 2024, a decrease of 28.6%.</li><li>Cumulative Systems Placed: 174 systems as of September 30, 2025, compared to 156 systems as of September 30, 2024, an increase of 11.5%.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company aims to achieve positive cash flow by the end of 2027, focusing on reducing cash use for operating and investing activities.</li><li>Non-Core Business: The company entered into a Distribution and Collaboration Agreement with MilliporeSigma to expand its market reach globally, with a focus on industrial quality control applications.</li><li>Priority: The company is prioritizing the expansion of its Growth Direct platform and increasing customer adoption, with a strategic focus on biologics and cell and gene therapies.</li></ul>

Rapid Micro Biosystems | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 7.838 M